A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

In a major scientific breakthrough, researchers at Mayo Clinic’s Center for Individualized Medicine have identified a rare genetic mutation that can directly cause a common liver condition—metabolic dysfunction-associated steatotic liver disease (MASLD),